Dimed S.A. Distribuidora de Medicamentos (BVMF:PNVL3)
Brazil flag Brazil · Delayed Price · Currency is BRL
11.04
+0.04 (0.36%)
Nov 17, 2026, 5:39 PM GMT-3
← View all transcripts

Earnings Call: Q2 2026

Aug 7, 2026

Summary

Q2 sales rose 15.8%, mature-store sales grew 11.4%, and market share reached 13.5%. EBITDA and net income advanced while gross margin eased; continued cash generation and deleveraging support 2030 growth and margin targets.

Good morning, ladies and gentlemen, and welcome everyone to Panvel's video conference to discuss results relative to Q2 2026. This video conference is being recorded, and a replay facility will be made available at the company's IR website. The respective slide deck is also available for download. All participants will be connected in watch-only mode during the presentation. After that, we will start a Q&A session when further instructions will be provided. Translations into English and into Brazilian Sign Language. To activate the functionality, click on the Interpretation button in the bottom of your Zoom screen. Before moving on, I would like to enforce that forward-looking statements are based on beliefs and assumptions of the company's management, and also on information currently available. Such forward-looking statements may involve risks, uncertainties, as they involve events that will happen in the future and that depend on circumstances that may or may not occur. Investors, analysts, and journalists should have in mind that events relative to the macroeconomic scenario, the industry, and other factors might lead to results that will differ from those expressed in the respective forward-looking statements. Here with us today, we have Mr. Julio Neto, CEO, and Antonio Napp, CFO and IRO. I would like to turn the floor over now to Mr. Julio Neto, who will start the presentation. Please, Mr. Julio Neto, you may carry on. Thank you. Good morning, everyone. It is a great pleasure to be here this morning to present relative results for Q2. Yet another quarter that presented a high level of consistency, proving that the pharma industry is truly an industry which is quite resilient. We have been monitoring the struggles that other retail companies have been facing, so the pharma does stand out. And within the pharma industry, Panvel has really stood out since we started reporting. This is the 25th quarter where we gained market share, six years in a row of market share gain. Quite consistent journey, followed, of course, by a growth in results, which is also important. The company in Q2 grew 16% or just about. An important highlight we should make, retail should always have this in its radar, is growth of mature stores. Our mature stores saw a growth of 11.4%, way above inflation, which shows the company's ability to absorb cost increases and still continue to grow in a very healthy manner. EBITDA has also grown above sales, reaching 88.5 million BRLs in Q2. And once again, the company has shown a cash generation level which reinforces the financial health the company has shown, including a drop or a reduction in debt throughout time. The operating results or highlights are all record-breaking numbers. All figures that you see on the screen are record, had not been achieved before. 13.5% of market share in the south of Brazil, a digital share which this time really went through the roof, and that's a trend that's here to stay. I will go into more detail down the presentation when we reach that point of the presentation to explain why digital tends to grow even more in the coming quarters. Panvel products. We are the main market benchmark in our own label products, and that's the main reason why consumers favor Panvel. We reach 19.9% in beauty and hygiene, and our average sale maintains an expansion pattern, which is quite important, and that helps us to dilute costs. Average sales is a metric we have been pursuing constantly. New stores have been showing important ramp-up momentum. We have been opening new stores in high-potential markets for good or very good average sales. We understand that this number will truly help us dilute costs so that we can reach our targets of having an EBITDA of around 7%, which is our target for 2030. If you look at the other figures on the next slide, quite significant as well. This is the year's results, six months, that shows that growth is truly consistent, has been so since 2022 first half until 2026, showing CAGR of 14.7, growth in sales 14.7%, and an EBITDA level showing a growth. You have the groups EBIT as well. The LTM, last 12 months, okay. The LTM is even better. Considers the whole year, as of the second quarter of last year, a CAGR of about 18.5%, leading to an EBITDA of BRL 350 million, a number that by the end of the year will probably go over that. We will get close to BRL 400 million in EBITDA this year. Next slide, please. Digital is actually an important highlight. We are a company that has always believed in convenience, in time-saving for consumers. We were never a company to understand that digital was a threat. Before the pandemic, or even that, we already had 10% of share, which was 10 times as much as our competitors at the time. We continue to believe that digital is a very important complement to our activities. Today, we understand, we see digital is not only a convenience for consumers, but it's also a relationship way for us to approach customers. We have been investing significantly in our app. We grew over 40% in Q2, getting close to 9 million downloads, over 420,000 deliveries at people's homes. In annualized numbers, we're talking about 4 million deliveries. When you look at the pie chart for sales, we see that proprietary channels, marketplace stands out, 11.4% of our sales, 11.4. The main highlight, under our app. Our app accounts for 63.4% of our sales. We are going to break that number down. We never actually did that, right, to have different pricing approaches for digital and physical stores. But now, with GLP-1, with an incentive from the industry, from the pharma industry, we see customers looking for those products at the store level to really conclude the purchase then using the app, and then having a benefit of BRL 100. So we created something simpler for customers. We have a QR code that can be accessed via the app. We read the QR code, and we identify the consumer by their taxpayer number. So it's a digital sale concluded at the counter, and we'll be breaking down that number. It's called App at the Store, as we call it, App at the Store. And that's what it is. It's an experience on the part of consumers. We saw a lot of migration of customers that would use the click and pick up at the store. That pie chart changed across the channels, but we would like to break that down to show the functionality of the app at the store channel, because we will have high digital numbers from here on. I am not going to mention the number now, but that is a trend, so that you know. The industry has been proposing a different pricing conditions for digital sales, and we are always trying to find a way to deliver that to consumers in a more seamless way. Digital has grown and grew in the second quarter, something close to 60%. We are talking about really impressive figures showing the company's solidity. Today, it has become a characteristic of the very industry, the level of digitalization of pharmacies and drugstores in Brazil as a whole is very, very high across the board. The speed with which drugstores deliver today is also very high across Brazil. For the industry as a whole, that is very good. Everybody wins. It is a good hedge, if you will, that the industry has developed, unlike the U.S. market, where the U.S. pharmacies are lagging behind when compared to digital. This is a protection buffer ahead for new entrants in this market. Next, we have our own brand, our private label numbers, 19.2% of share, as I mentioned, overall sales. We start to have the number without the GLP-1, because GLP-1 has an important share. Without GLP-1, it is 8.5% of total shares, and with GLP-1, still is a record at 7.5% of share. That is a hot topic, as you know. That is what makes us stand out. You are all invited to access social media, Instagram, TikTok, whatever, and you type in Panvel, and you see the amount of content that our private label has been able to provide. That makes Panvel a young, innovative brand, also accessible. To a very young audience. Through our private label, we have a very young public coming to the drugstore. In terms of the beauty cosmetic products, not only for our private label, but the share of sales, we have become authoritative brand, 33% of share and sales in cosmetics and hygiene products. That is something we know how to do, and we do it really well. It is a quick example here of a recent launch. Three months ago, we launched our new makeup line. We had Panvel Make Up, now we have Panvel 24&seven. That will be our makeup brand from here on end, Panvel 24&seven. It is a huge success. The sales share in makeup with our private label succeeds or, I mean, exceeds 50%, and a profitability of 70% above the other brands that we sell. Through those launches, we create the sort of a buzz, if you will, with a very aggressive digital communication that runs across Brazil. We sell that across Brazil, and we are quite happy with the level of innovation that our own products have brought to the market. Our private label is one of the main ways we have at hand to stand out amongst our competitors. Our brand sounds good across different products, very much unlike our competitors, because their own brands do not have the necessary flexibility to endorse products with the same appeal that we have. We are much sexier than our competitors, if you will. Now I am going to turn it over to Napp, and he will go into more detail around the numbers. Then I will be back for the Q&A, okay? Thank you, Julio. It is a pleasure to be here this morning with you. I will walk you through our main numbers now, and then we will be available for questions. We already sort of anticipate what the questions will be. Oh, sales, anyway. A strong growth in sales, 15.8% in the quarter. It is worth mentioning that yet another quarter in which most of the growth came from the number of services with clients. Panvel is very efficient in bringing more clients or customers into the stores, both physical and virtual, and that has boosted us. That shows in a strong growth in average sales, BRL 819 thousand on average per store, a 13% growth, which is way above inflation. Our mature stores, three years old or more, BRL 870,000. Very soon, we will be reaching BRL 900,000 per store. On the bottom part, it is difficult to read because we no longer have a store selling up to BRL 300,000. They all sell more than that. We have been doing a good approach through all our channels, services, our private label, to ensure a spread out growth across our chain. When we compare with competitors, it becomes clear that Panvel continues to open the alligator's mouth, as we say, creating this gap from the competition across all figures. It has to do with the good relationship work with customers. We have been increasing our customer base through stores, through agreements. We have a fishbowl of 31 million clients, as we say, and the idea now is to activate and make them loyal customers. Digitalization, as Julio said, has been key in spinning up that database or customer base. We are growing active customers, loyal customers, and omni clients as well. Omni customers are those who buy across all channels, and that is what we are looking for. We also launched in this quarter, officially launched our Panvel Prime to identify our prime customer within our app. It is a very representative base. It is our higher value customer, and we have been reaping a lot of benefits from that initiative through more engagement, more frequency, and we are working hard to maintain that base. When we look at the whole system, it becomes clear why Panvel has been growing well and delivering benefits to those customers, of course. That is a group of customers that are very loyal to our brand, to Panvel. We have created a volume and amount of benefits, not only to retain or maintain them active, but also to increase the prime database. So free freight, people choose their products at the best price in the market, a series of benefits that we offer those prime customers. Vaccination, shots, series of benefits that prime customers do not pay for. That increases engagement. We concluded that it is not worth our while to invest across all types of clients. We need to choose those clients who will be higher LTV throughout time. It is to better explore our fishbowl, as we call it, right? This has to appear in our mature same-store sales, as Julio has already said. I would just like to add that this is one of the main highlights of our quarter. Comparing to the base number, to the competition as well, we did something quite different. Our number of stores, we did not open many stores in the first half. We are using other levers. In other words, a very healthy growth journey. We will be talking about GLP-1 as well, but what we would like to highlight is the following. Panvel is a network that brings balanced growth across all product categories. We like to say we are not a retail that works around one category. We have over 10,000 SKUs at the stores, and we have been doing this for a long time. Brand medications grow well. Of course, GLP-1 is here, but even if you exclude GLP-1, we have a robust growth. Our share in generics continues to grow. That grew 18%. Health and beauty, 14%. As Julio said, beauty and cosmetics is a competitive edge that we have. When we look at this across time, we have a CAGR from 2022 to 2026, the word I like to use is balanced, equilibrium. The growth in medications and the growth in non-medications, non-drugs, is very similar, very balanced. That has to do with the profile of our customers, and also has to do with the maintenance of a very healthy gross margin. That is what you are looking for. We have an environment of stores to sell a lot of SKUs, and we meet the demands from all types of clients, customers. At the end of the day, if we are servicing our customers well, it is because we have quality service. Our NPS continues to grow, 82 points now, and continues to grow. When you look at the metrics of CSAT, 96 points. Our app is the best assessed, both at the App Store and at Google Play. NPS is a target for all our stores. We have an NPS measured by store. Managers are looking not only at the number, but also at something more important, in my opinion. They are looking at the comments made by consumers. What could be better at the store level? That helps us put together action plans. If we are doing this well, that of course translates into the market share. We grew one percentage point in market share in the quarter, 13.5%. We have been growing that number for 25 quarters, as you said. What catches our attention in this quarter is the growth of our more mature base, Rio Grande do Sul. We grew by 1.1%. That is quite important. We have not stopped growing in Santa Catarina and also in Paraná. When we break that number down and we compare with the rest of the market on other chains, independent drug stores, our quality stands out. In the south, we grew 8%, the overall, but we grew 16%. We grew more than everybody else, both in volume and in average price. So it is a lot of quality. Without losing the focus on our value proposition, we are quite focused on health, beauty, and well-being. We see our competitors, especially regional competitors, trying to grow sales, expanding mix, bringing consumers a sort of confused proposal, maybe taking up the space that the Americanas chain left empty, perhaps. I don't know. We work the medication industry really well. It's not an easy market. Supermarkets will now face this challenge of working with medications in terms of logistics, inventory management, no easy task. Our focus shows that keeping the focus actually is the right thing to do. We grew across all categories, the 1.3% in medications, as you just mentioned. For brand medication, 1.6%. That's also a highlight. Generics also a highlight. Increasingly a highlight. We still have room to grow in generics, of course, to reach 13%, which would be the fair share. There's a huge opportunity there, and we have been reaping good benefits. Throughout time, we tend to expand margin, both generics and OTC. After talking about sales, we talk about gross margin. We continue to have a healthy gross margin, 30.1% at the end of the quarter. There's a slight pressure when compared to last year when we posted 30.4%, but that pressure comes from well-known factors, a readjustment below inflation, a strong growth in GLP-1 or brand categories, which pressures margins. In terms of cash margin, we have very positive results. Even with those pressures, which are structural market pressures, we still have several other elements which have ensured that we have counterbalances. We work very well around our private label, generics, beauty, and health. That's our focus. The long-term trend of gross margin is to slightly drop, but we have excellent levers to maintain our gross margin at a very healthy level. We move to one of the main highlights of the quarter, which is with this huge performance in sales. With a very rigid expense control, we have been managing to obtain nice or very good gains in expense reduction. We reduced sales expenses by 0.7% quarter-on-quarter, and 0.2% in admin expenses. Those gains are structural. We continue to increase our productivity per store. We continue to control expenses, and at every quarter, we will have larger gains. Shedding a little bit of light on that, we show our four-wall EBITDA. The four-wall EBITDA is a concept of contribution margin coming from the stores. The results coming from our stores only. From one quarter to another, we grew over 17%, expanded by 0.2 percentage points, and it's a simple math. Our gross margin was pressured by 0.3 percentage points, so we improved our store expenses by 0.5%. Simple math. This will continue to happen. This way, we can see that throughout time, the CAGR for four-wall EBITDA from stores will exceed 60%, way above sales. That has to relate with the quality of our expansion. As Julio mentioned, we open fewer stores. We'll speed that up in the second half, but we follow all the seasons. The two main takeaways, our seasons continue to deliver EBITDA, which are quite robust and growing, very good in growing return on invested capital. When we look at a breakdown per state, it becomes really clear that every state is pursuing margin and EBITDA that we post in regard to our most mature base. Santa Catarina, we are at 11.1%, and that's an LTM number. Paraná, 9.5%, and São Paulo, 6.3% and growing. Those numbers increase or improve every quarter because there is a lot of base to mature over. We are quite satisfied with that. That's yet another margin booster for the coming quarters. Our EBITDA for the group, and the message is the same. We continue to grow quite robustly, over 26% quarter-on-quarter. We have reached 5.4%. If we look throughout time, analyze our CAGR, we are now sitting at 15.4%. We have not stopped growing numbers, very healthy numbers. The same thing goes for net income. Our net income in this quarter grew by more than 39% when compared to Q2 2025, an expansion of 0.4 percentage points. I'd like to highlight the growth of our income before income tax, which grew 34%. We are managing to grow operationally. Our debt, we're going to be talking about in a moment, we continue to deleverage our debt. We have improved our cash, so interest rates account for increasingly less weight. We have a better profit than EBITDA. We're quite happy with that. Julio, we always do that. I'd like to take the opportunity to thank the whole team, all our employees. These results are thanks to the efforts put in by everyone. Thank you. To finish, wrap up the numbers, the icing on the cake, the cash cycle and debt level, we continue to deleverage. We have a very low debt level already, and we continue to focus on deleveraging that debt. It's a huge edge that we have. We know that several competitors have a much higher debt level, and that has been stifling their growth possibilities. Having low debt, a well-organized balance sheet is a differential. A stable cash flow. We have generated free cash flow for the sixth consecutive quarter, especially in the first half of the year. You know that seasonally, that doesn't happen in the first half. We continue to be disciplined, and we are pursuing to further deleverage the company, growth and deleveraging it side by side, and that's something we have been managing to do. After talking about all those numbers, we are getting close to the end, but I'd like to go over a few recaps. Where are we headed? This is our guidance. You know this from our Panvel Day. We're looking ahead, looking at 2030, and we're working to double the size of the company, reach an EBITDA of 7%. This is the start of the journey. It's a very promising start of a journey. We are quite happy and looking in our rear-view mirror, 2026 to 2030, that's brick by brick, of course, and the first bricks, if you will, of our new home, if you will, are quite solid. We have delivered the first half, which was quite strong, a growth in sales and a growth in bottom line. I'd like to highlight on the bottom part of the screen, this last 12 months view, the LTM view. They start to show how we are managing to move our indicators upwards. For the past 12 months, we have grown sales at a very strong pace of 16%. We have grown EBITDA at the pace of 22%, moving from 5.2% to 5.6%. Let's remember that in the second half of the year, that's when we have higher margins. We will get close to 6% by the end of the year. The retail EBITDA and EBITDA four-wall at the same pace, and of course, net income also showing a growth of 24% last 12 months. When you look at our EBITDA and our deleverage debt, we will be growing that 2.5% by the fourth quarter of 2026. That's why, looking back here, we like to reinforce the future. We know that the first half of the year, especially when we talk to analysts or the banks, some clouds or questions emerge, and we continue confident that the pharma retail continues to be one of the best, if not the best retail market in Brazil. Market consolidation will continue to happen, and Panvel continues to be a very important player. We are delivering premium execution. We are located in a region that grows faster than the rest of Brazil. We operate in a very fragmented market, and we have all the tools to continue to explore all of that. One of the elements I have already mentioned, we know the questions will appear about this, GLP-1, without a doubt, is a structural factor. We continue confident, and we are sharing some numbers. Before that, it's good to reinforce. We want the market to understand this dynamic. It's worth mentioning that Panvel is a highlight in GLP-1. GLP-1 consumers are coming to us. In the south of Brazil, our share is about 30%, 330. That's a lot. It's an overshare, if you will. For GLP-1, if you're navigating that area, those waters, and you know that not every chain is doing that. What does that chart show? The price effect we have now with more competitors coming in. There were some doubts. We have no doubts. The numbers show that the reduction in price brought an expansion that was way above the price difference. That has to do with sales, that has to do with more customers, and for networks and chains such as Panvel, that has been really, really good. We have been capturing more gain than the average chain. More medications are about to come to Brazil. Competition will increase, and this will bring a positive pressure on the gross margin line. The gross margin for those products are still lower than average, but the trend throughout time is to have better pricing and better gross margin. That's a very important factor to take into account, and we are paying close attention to that. Another fundamental aspect here, Julio has already reinforced that, is the work being done around digital, digitalization of clients, all the structure we have. Not all chains can do that. This is what sets us apart. This is what allows us to grow healthily, and we will continue to remain engaged here because we understand that this is one of the main levers that will allow Panvel to continue to grow beyond market growth, and also will allow us to defend ourselves from the competition. When we combine all those factors, it's only natural that we continue to look for the rest of the year with a lot of optimism. We are confident in the sales growth. The sales in July already show an acceleration. Of course, we need to wait for August and September, but what we've seen in July, we can say numbers will grow. There is a strong trend for sales to speed up. As I said, gross margin will suffer some pressure, as I said, but through expense dilution, we will be able to deliver increasingly higher EBITDA. We continue to focus on cash generation, and with that, the company continues to grow. With that, I close this part of the presentation, and Julio and I are available for your questions. Thank you so much for your attention so far. We will now start our Q&A session for investors and analysts. If you have a question, please click on the raise hand button. If your question has been answered, you may remove yourself from the queue by clicking on lower hand. Our first question comes from Vinicius Pretto from Itaú BBA. Mr. Pretto, you may carry on. Good morning, Julio and Napp. Thank you. I would like to explore two topics with you. Number one, we have to talk about GLP-1, I know. Then the elasticity on the side of demand. We showed very nice numbers in terms of price evolution, volume evolution, sales, after new medications coming in. I would like to better understand how you see demand behaving after that, and to explore a possibility of new customers, because now you have customers buying other brands through other channels, and if you see any migration from customers that change medication because of price. Also around GLP-1, what do you expect to see things happening in Q3, now that we have more stable supply? Also expenses, that was a very positive surprise. I would like to better understand what were the main drivers for that expense dilution, especially sales expenses, very positive results. Looking forward, what other drivers you have to capture expense reduction? Do you see a need to reinvest part of those gains? Thank you. Thank you, Julio. Thank you, Vinicius. GLP-1 then. I think first piece of data, when you look at clients, that is a persistent question we have. That increase in sales, when we look by customer, we see, well, this is a short story. We are talking about the half of June and July, right? But a little more than half of customers are new customers that had not bought with us yet, no products in that category. If they were buying elsewhere, we do not know, but we have seen an increase in the number of customers, and that has to do with an increase in our base as a whole. We saw our base growing. We saw other products growing as well. So we are bringing more customers in because of that drop in price. That is a first point. In terms of migration, that is not happening between medications. Mounjaro clients are very loyal to the product. We do not see the migration from Mounjaro to other products. That is not happening. Semaglutide needs a prescription, of course, at least up until now. This will change, of course. They are not interchangeable, right? With Ozivy, you have to have a prescription, otherwise we cannot sell. We cannot replace Ozempic by Ozivy. As for expenses, that is a main highlight. Still on GLP-1, the opportunity is huge, of course. I think you all know that TV stations are daily covering that and talking about the informal market, which is huge. A piece of data I can share, there are no more syringes in Brazil to sell. I thought it was for druggies or drug addicts. No, it is to inject Mounjaro or other, Ozempic, or coming from Paraguay. That is impressive. Syringes are sold out. The informal market is three times as large as the formal market, to give you an idea. When we see prices coming down, generics coming in, the opportunity is exceptional, right? Not only in sales growth, but also for growth in margins. We have been posting GLP-1 margins, which are somewhat restricted to the fact that they are linked to brands. We are talking about 17%-19% margins. For generics, we are talking about 50% margins. We are quite optimistic about the future of GLP-1 at the drugstore level for those two reasons. The informal market is right there. It is making the headlines every day, and to make consumers aware of the danger of injecting informal products coming from I do not know where. That drop in price will certainly bring a lot more customers to the drugstore, something we have never seen before. A lot of work being done here. We have logistics, also important. As for the store, the main highlight is that we have managed to dilute personnel and lease expenses. We have been revisiting our processes. We have been removing bureaucracy from the stores, and that has allowed us to grow sales without increasing headcount. As sales continue to grow, we continue to have gains on the personnel level and on the lease level. Of course, we are working along other fronts, materials. Those are lower accounts, so important, but lower. I would like to highlight personnel and lease. When we talk about logistics, we have come to yet another quarter where we have more productivity on our logistics arm. Our both distribution centers are now showing the results of the investments. We started working on it back in 2025. We have already reduced our logistics expenses, and we continue to capture gains in 2026. We understand that moving forward, those moves will not change because we continue to be optimistic for sales, and we do not see pressures coming from expenses or extra pressures from expenses. Okay, thank you. Thank you. Our next question comes from Laryssa Sumer from XP. Ms. Sumer, you may carry on. Good morning, Julio, Napp. Thank you, and congratulations on your consistent results. I have a quick question on GLP-1, and then I will change gears, right? As for GLP-1, you talked about your overshare in the category. If you could comment on how you see the execution of the competitors. Is there any bottleneck? Where are you doing your homework better than the competitors? Another topic is the following. You talked that you are not still in the fair share level for generics. You have been improving results, but there is still a gap, there is still room to grow. If you could give us a little more detail about what kind of opportunities you see you have in generics, that would be nice. Thank you. Okay, as for GLP-1, and when we look at the competition, well, number 1, there is a very positive convergence between the Panvel customer. It is still an expensive product. It is an expensive product, that is the first thing. But there is a second element which is also important that has to do with our focus. You need to have inventory, availability, logistics. Because we are quite focused on health, we have local competitors who today sell things which are quite different from what we sell. Because of that, customers who are looking for health products still favor Panvel because we are specialists. As we also dedicate ourselves to digital, GLP-1 has become a product which has been 100% digitalized, so it is easier to buy at Panvel. We made people's lives a lot easier through digital channels, through our app. The experience is quite fluid, quite seamless. A company in the sector said that for them, digitalization was a problem in Q2. We are talking about a profile of customers who focus on health and who have very good digital literacy, and that helps GLP-1 to stand out within Panvel's activities. Your second question, Laryssa, about generics, the fair share, that is true. When we look at our share of generics, and OTC as well, it is not at the same level of our overall share, which is 13.5%. When we look at the competition, there is room to grow. The good news is that we have been bridging that gap throughout the last two years, I would say, in generics. We are growing a lot more than the market. There is still room of at least 2 points to grow in generics, which is a lot of growth, I have to say. As we are growing more generics than the remainder of the company, we are quite happy because we are talking about more clients. There is also a movement, Napp. GLP-1 somehow has encouraged migration to generics because it consumes an important portion of families' income. They were led to cheaper products. Customers are more aware, are more price-aware when they come to our stores. I think it is our mission as a drugstore to provide access. We continue to be very optimistic, and as I said, a couple of points to be pursued in generics. Of course, that is not going to be captured in one quarter, but we will do that throughout 2026 and 2027. Thank you. Congratulations once again. Thank you, Laryssa. Our next question comes from Mr. Lucca Biasi from UBS BB. Mr. Biasi, you may carry on. Good morning, Julio. Good morning, Napp. Thank you. I have two questions. Number 1, about the gross margin. It would be nice to know if you could quantify the impact of that increase of GLP-1 in the gross margin, and also comment on how you see the gross margin for different GLP-1 medications. When Ozempic arrived, margins were a little below expected. If similar medications have impacted the margins of other medications, Mounjaro and semaglutide. In terms of working capital, do you still see room for improvement across the three main working capital lines in the short, in the mid-run? Thank you. Let us talk a bit about gross margin. Lucas, thank you for your question. Gross margin, okay. GLP-1 in the first half or quarter, it accounted for 12% of our sales, and we are talking about products of gross margins below 20%. Of course, that brings on a pressure on gross margin, and that is why we lost 0.3%. It is a lot of sales across items that suffer some pressure. As you well know, the first similar, Ozivy, did not show a higher margin, but we are quite optimistic with the dynamics. As we have new competitors coming in, we showed in the slide at least another five products to arrive in Brazil very soon. We believe that the best solution is for the competition amongst suppliers. That will improve sales conditions for the drugstores. As we move forward, we continue to improve margins. We are focused here. Of course, we would like to have the highest possible percentage, but we also need to look at the cash margin. It is a high-ticket product, even cheaper products. How much are we keeping from them? That is a very positive relation when you look at the cash margin vis-a-vis the amount of new customers. That is why our profitability curve and our EBITDA curve is moving upwards. That is how we think about it, okay, Lucas? As for working capital, yes, we do have that lever. We understand there is room to work in terms of payment terms. There might be some space in inventory days, but when we look at our opportunity map, looks like payment terms is the low-hanging fruit now. Our inventory level, when we look at the market, it seems to be quite well-balanced. Of course, there are opportunities, but it seems to be balanced. Our focus is on payment terms, something we have to talk with clients, of course, customers, but having stable terms. We are concerned about not being very much leveraged, and we are doing a good job on that front. Okay. Thank you. Thank you, Lucas. Our next question comes from Mr. Yan Cesquim from BTG. Mr. Cesquim, you may proceed. Good morning, Julio and Napp. Two questions. First, about HPCs. Good news. We saw that. I would like to understand the drivers for growth in that category and what you expect going forward. The second question about GLP-1s. It is difficult to get away from that topic, as you know. I would like to better understand how you see the supply dynamics for the new similar drugs. What have you observed throughout the first two weeks and the quarter for Ozivy? How were the talks with the industry? We are now going through the second round of registrations. How long until those medications hit the stores? Is that part of your plan? To what extent for the second half of the year? So a bit qualitative, but just to understand the dynamics. Okay, thank you. Well, in terms of supply is really well, really good. Ozivy is a sales success, a sales hit, I can tell you that. The Federal Health Agency is to be congratulated on what they did. The product, to give you an idea, the product only accounts for 20% of what we sell in that category, GLP-1. Now we have Hypera coming with a product. Others will come. We are anxiously waiting for generics because we have a higher margin. As Napp said, the cash margin for the category is really good. If we take into account how much it costs to separate a product for high blood pressure that costs BRL 20, it is the same price to separate Mounjaro, which costs BRL 2,000. So in logistics terms, it is much better to separate an expensive product than a BRL 30 product. So even with a lower margin, it is a very good product for us. What we have seen in terms of supply is that the Mounjaro supply has been consolidated. We are past that. Balance seems to have been found in terms of supply. It couldn't be found for some time, but it has finally reached its market share potential, so not a longer process. The whole category, of course, has a growth potential which is nothing short of fantastic. Itaú did a study. They did a study, and they are talking about 20% of share. We were thinking that that was a crazy estimate, but it could happen. It could happen. Once that happens, as we grow generics and health and beauty, we're looking at a company with a potential of having a CAGR, which is going to be impressive in the coming years. Panvel is known for providing a great experience along health and beauty, and that sustains our growth. You saw 14%, almost 14% in beauty and hygiene. We have come a benchmarking beauty specifically. We are one of the few chains that can work well with makeup, for example. We are a destination shop for women who want to look better, more beautiful. So that also helps explain the good performance in beauty products, without a doubt. The perspective, the outlook is really good. We are quite happy to have delivered those numbers, and we see that trend as being positive. Of course, through all time, some categories perform better than others, but the overall approach is really good, and beauty continues to be a growth driver, no doubt about it. Thank you. Thank you so much. Thank you, Yan. Our next question comes from Mr. Henrique Spavieri from Bradesco BBI. Mr. Henrique, you may proceed. Good morning, Julio, Napp. Thank you for taking my question. I have two questions. One, for same stores, sales in mature stores continues to be strong, good contribution from GLP-1, some bases becoming more difficult. What do you see that indicator from a structural point of view, considering productivity per store, volume, mix? Also, specifically about GLP-1, could you comment on the relevance of the combo programs linked to that category, and if you see any effect of people buying more or cross-selling? Thank you. The combo is a fantastic tool to introduce consumers to the category. There's a huge buy-in. The price advantage is very, very big. GLP-1, our mature stores, of course, GLP-1 is a booster, but the number is not in the presentation. If we exclude GLP-1, our mature stores are going by 8%, way above inflation. So those are very robust numbers, even without GLP-1, for same stores, same mature stores. Julio hit the nail on the head. If you look all the way through 2030, we will keep that growth in one high digit. Now, with GLP-1 growing at that pace, we won't be surprised if that number goes up to two digits. Structurally speaking, of course, we always start to manage everything with and without, with and without. I have answered this question many times. I'm not concerned. I'm not going to depend on GLP-1. I'm not concerned with that. The future for that drug is great. The future, we used to have several suppliers. When you have several suppliers, there is no problem. Could be 20%, 30%, whatever the category represents. It's important to have the rest of the categories growing at healthy rates. We understand healthy basis to be around 13%, 14%. If everything is growing at that pace, whatever growth GLP-1 posts, it is so much the better, so much the better. It is what we call balance. Everything has to grow, and our targets are also segregated. We have targets with and without GLP-1. I think we answered your question, right, Henrique? Okay. Sorry, go ahead. The other question was about how do you see frequency with the combos and cross-selling? Recurrence is really good. Consumers who use GLP-1 to lose weight, there is some aesthetic-based use. Just before summer, they buy two boxes, they use it for two months, that kind of thing, to lose a couple of kilos. But those who really need to lose weight, they are doing the treatment very seriously. Then we sell 12 boxes. Yeah, 12 boxes. Four injections per month. Yeah, 12 boxes, yes. So they will consume 12 boxes throughout the year. The buy-in to the treatment is very good for those who take the treatment seriously, people who really want to lose weight for health reasons or to control diabetes, which was the first objective, right? As I mentioned before, more than half of the new customers are new customers coming to the store. We are not seeing people buying products beforehand. In July, we saw growth, as I said. I think it is a trend. Okay, thank you. The Q&A session is now over. We would like to turn the floor back over to Mr. Julio Neto for his final remarks. Well, thank you once again for the questions, for being here. I heard from a banker once that analysts are good because they become better managers. You have been doing that with us. We have become better managers because of your questions, because of your thought-provoking comments. Thank you so much, and we will see you for the next call. Thank you for your public, for your audience, for those watching us live, and all the others, and enjoy the weekend. Grupo Pão de Açúcar's video conference is now over. Thank you all for participating. Have a nice day, everyone.